JP2012532854A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532854A5
JP2012532854A5 JP2012519055A JP2012519055A JP2012532854A5 JP 2012532854 A5 JP2012532854 A5 JP 2012532854A5 JP 2012519055 A JP2012519055 A JP 2012519055A JP 2012519055 A JP2012519055 A JP 2012519055A JP 2012532854 A5 JP2012532854 A5 JP 2012532854A5
Authority
JP
Japan
Prior art keywords
methyl
thiadiazol
formula
compound
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519055A
Other languages
English (en)
Japanese (ja)
Other versions
JP5982281B2 (ja
JP2012532854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2010/001315 external-priority patent/WO2011004162A2/en
Publication of JP2012532854A publication Critical patent/JP2012532854A/ja
Publication of JP2012532854A5 publication Critical patent/JP2012532854A5/ja
Application granted granted Critical
Publication of JP5982281B2 publication Critical patent/JP5982281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519055A 2009-07-08 2010-07-08 医薬として有用な化合物 Active JP5982281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21373509P 2009-07-08 2009-07-08
US61/213,735 2009-07-08
PCT/GB2010/001315 WO2011004162A2 (en) 2009-07-08 2010-07-08 Compounds useful as medicaments

Publications (3)

Publication Number Publication Date
JP2012532854A JP2012532854A (ja) 2012-12-20
JP2012532854A5 true JP2012532854A5 (https=) 2013-08-15
JP5982281B2 JP5982281B2 (ja) 2016-08-31

Family

ID=43086401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519055A Active JP5982281B2 (ja) 2009-07-08 2010-07-08 医薬として有用な化合物

Country Status (24)

Country Link
US (2) US9162994B2 (https=)
EP (1) EP2451794B1 (https=)
JP (1) JP5982281B2 (https=)
KR (1) KR101765957B1 (https=)
CN (1) CN102596923B (https=)
AU (1) AU2010270030B2 (https=)
BR (1) BR112012000370B1 (https=)
CA (1) CA2767291C (https=)
DK (1) DK2451794T3 (https=)
EA (1) EA026674B1 (https=)
ES (1) ES2567753T3 (https=)
HR (1) HRP20160353T1 (https=)
HU (1) HUE027263T2 (https=)
IL (1) IL216723A (https=)
ME (1) ME02443B (https=)
MX (1) MX337516B (https=)
NZ (1) NZ597075A (https=)
PL (1) PL2451794T3 (https=)
RS (1) RS54718B1 (https=)
SG (1) SG177558A1 (https=)
SI (1) SI2451794T1 (https=)
SM (1) SMT201600225B (https=)
WO (1) WO2011004162A2 (https=)
ZA (1) ZA201108901B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931145B1 (ko) * 2008-07-04 2009-12-10 현대자동차주식회사 조정식 킥 다운 스위치의 조작기구
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
PL3571193T3 (pl) 2017-01-23 2022-04-25 Cadent Therapeutics, Inc. Modulatory kanału potasowego
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
EP3870291A1 (en) 2018-10-22 2021-09-01 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
WO2020095010A1 (en) 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
CN109879808B (zh) * 2019-03-05 2020-10-16 北京工业大学 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途
GB201910092D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201910093D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
WO2025017194A1 (en) 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler
WO2025017193A1 (en) 2023-07-20 2025-01-23 Betagenon Ab Methods of treating cardiomyopathy induced by metabolic inflexibility
WO2025027205A1 (en) 2023-08-03 2025-02-06 Betagenon Ab Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
MXPA02011079A (es) 2000-05-11 2004-08-19 Consejo Superior Investigacion Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
WO2006045581A1 (en) 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
US20090156644A1 (en) 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity

Similar Documents

Publication Publication Date Title
JP2012532854A5 (https=)
JP5982281B2 (ja) 医薬として有用な化合物
US5399566A (en) Pyridine derivatives having angiotensin II antagonism
JP3298641B2 (ja) イミダゾール誘導体およびそのサイトカイン阻害剤としての使用
US20100311748A1 (en) Heterocyclic amides useful for the treatment of cancer and psoriasis
US20050203153A1 (en) Phthalimide carboxylic acid derivatives
KR20110091865A (ko) 2h-크로멘 화합물 및 그의 유도체
RU2442777C2 (ru) Ингибиторы киназ и способы их применения
EP1836173A4 (en) ANTI-INFLAMMATORY DRUGS
JP2006528193A (ja) C−fmsキナーゼの阻害剤としてのキノリノン誘導体
AU2009200478A1 (en) Metabotropic glutamate receptor-5 modulators
SK242590A3 (en) Substituted n-(aryloxyalkyl)heteroaryl piperidines and -piperazines, method for their preparation and pharmaceutical compositions containing same
AU2005270132A1 (en) Anti-inflammatory medicaments
PL203771B1 (pl) Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu
JP2005539000A (ja) Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体
JP2017502057A (ja) ブロモドメイン阻害剤としての二環式複素環誘導体
JP2008266295A (ja) キナーセ゛阻害活性を有する新規チアシ゛アソ゛ール誘導体
AU2002238855B2 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
CA2803880C (en) Compounds for the inhibition of cellular proliferation
CA3136725A1 (en) Inhibitors of cd40-cd154 binding
WO2001058880A1 (en) Novel triazole derivatives
RU2287529C2 (ru) Новые гетероциклические производные и их медицинское использование
KR20070116876A (ko) 피리미딘 카르복실산 유도체 및 그의 용도
KR20150012289A (ko) 항바이러스 활성을 가진 메탄티온 화합물
AU2004262482A1 (en) 2-`4(phenylamino)-piperidin-1-yl-n-phenyl-acetamine derivatives and related compounds as neuropeptide Y5 (NPY5) ligands for the treatement of obesity